Skip to main content
Exclusive Savings: Take 10% OFF All Cenmed Products | Upgrade Your Lab For Less Shop Now
US English

ALADDIN SCIENTIFIC

AZD-8529 (C008B-268083)

AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2 , with an EC 50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1 , 3, 4, 5, 6, 7, and 8 subtypes.In...

Description

AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2 , with an EC 50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1 , 3, 4, 5, 6, 7, and 8 subtypes.In VitroAZD-8529 potentiates the effects of glutamate at mGluR2 with an EC 50 of 195 nM. AZD-8529 does not elicit antagonist responses on mGluRs at 25 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoAZD-8529 (0.3-mg/kg, i.m.) reduces nicotine priming-induced and cue-induced reinstatement in squirrel monkeys . AZD-8529 (30 mg/kg; i.p.) decreases the increased extracellular dopamine induced by nicotine in accumbens shell of freely-moving rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Sprague-Dawley rats Dosage: 10 mg/kg, 30 mg/kg Administration: Intraperitoneal injection; 2 hours before nicotine injections Result: Decreased the increased extracellular dopamine induced by nicotine (0.4 mg/kg, s.c.) in accumbens shell of freely-moving rats.Form:OilIC50& Target:mGluR2 285 nM (EC 50 )


Specifications & Purity: AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2 , with an EC 50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1 , 3, 4, 5, 6, 7, and 8 subtypes.In VitroAZD-8529 potentiates the effects of glutamate at mGluR2 with an EC 50 of 195 nM. AZD-8529 does not elicit antagonist responses on mGluRs at 25 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoAZD-8529 (0.3-mg/kg, i.m.) reduces nicotine priming-induced and cue-induced reinstatement in squirrel monkeys . AZD-8529 (30 mg/kg; i.p.) decreases the increased extracellular dopamine induced by nicotine in accumbens shell of freely-moving rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Sprague-Dawley rats Dosage: 10 mg/kg, 30 mg/kg Administration: Intraperitoneal injection; 2 hours before nicotine injections Result: Decreased the increased extracellular dopamine induced by nicotine (0.4 mg/kg, s.c.) in accumbens shell of freely-moving rats.Form:OilIC50& Target:mGluR2 285 nM (EC 50 )


Grade: Moligand™


Molecular Formula: C24H24F3N5O3


Molecular Weight: 487.47


EC Number: 680-652-6


PubChem CID: 25125217


Isomeric SMILES: CC1=CC(=CC2=C1C(=O)N(C2)CC3=CC=C(C=C3)OC(F)(F)F)C4=NC(=NO4)CN5CCNCC5


Storage Temperature: Store at -20°C


Shipped in: Ice chest + Ice pads


Specifications
UPC:
51372800
Weight:
1.09 Ounces
HazmatClass:
Yes
Quantity:
1
Unit of Measurement:
EA
WeightUOM:
LB
MPN:
A646690-25mg
Country of Origin:
China
CAS:
1092453-15-0
Product Size:
25mg
Harmonized Tariff Code:
2931.90.90
Catalog No. C008B-268083
Price: $413.48
List Price: $459.42
  • Guaranteed quality & reliable delivery
  • Shipping Lead-Time: 14-21 Days
Adding to cart… The item has been added
Request a Quote

Enjoy exclusive benefits, including discounted pricing on bulk orders, by opening a Cenmed Business Account. Learn More.